Literature DB >> 16517061

Amarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis model.

Prosenjit Saha1, Suvra Mandal, Ashes Das, Sukta Das.   

Abstract

Swertia chirata, is a bitter plant, used in the Indian system of medicine (Ayurveda) for various human ailments. Our laboratory was the first to report the chemopreventive effect of this plant. The antiproliferative and pro-apoptotic action of amarogentin rich fraction of S. chirata is now demonstrated on a mouse skin carcinogenesis model. Immunohistochemical localization revealed a reduction in proliferating and increase in apoptotic cells in skin lesion following treatment, also reflected in the expression of molecular markers--Cox-II and caspase-3 proteins. It may be possible to calculate relative risk, relative protection and attributable risk from the action of test agents on proliferation and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517061     DOI: 10.1016/j.canlet.2005.12.036

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  LC-ESI/MS determination of xanthone and secoiridoid glycosides from in vitro regenerated and in vivo Swertia chirayita.

Authors:  Vijay Kumar; Sheela Chandra
Journal:  Physiol Mol Biol Plants       Date:  2014-12-23

2.  Amarogentin Induces Apoptosis of Liver Cancer Cells via Upregulation of p53 and Downregulation of Human Telomerase Reverse Transcriptase in Mice.

Authors:  Chun Huang; Runqin Li; Yinglin Zhang; Jianping Gong
Journal:  Technol Cancer Res Treat       Date:  2016-07-11

3.  Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach.

Authors:  Bharat B Aggarwal; Sahdeo Prasad; Simone Reuter; Ramaswamy Kannappan; Vivek R Yadev; Byoungduck Park; Ji Hye Kim; Subash C Gupta; Kanokkarn Phromnoi; Chitra Sundaram; Seema Prasad; Madan M Chaturvedi; Bokyung Sung
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

4.  Amarogentin ameliorates diabetic disorders in animal models.

Authors:  Ho-Shan Niu; Pin-Chun Chao; Po-Ming Ku; Chiang-Shan Niu; Kung-Shing Lee; Juei-Tang Cheng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-03       Impact factor: 3.000

5.  Impact of Amarogentin on Gastric Carcinoma Cell Multiplication, Apoptosis and Migration via circKIF4A/miR-152-3p.

Authors:  Zhi Tan; Weining Wang; Jin Peng; Zhen Zhou; Jia Pan; Aiming Peng; Hui Cao; Wenling Fan
Journal:  J Immunol Res       Date:  2022-06-14       Impact factor: 4.493

6.  The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.

Authors:  Shantanu Shukla; Khushboo Bafna; Durai Sundar; Sunil S Thorat
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

7.  Amarogentin, a secoiridoid glycoside, abrogates platelet activation through PLC γ 2-PKC and MAPK pathways.

Authors:  Ting-Lin Yen; Wan-Jung Lu; Li-Ming Lien; Philip Aloysius Thomas; Tzu-Yin Lee; Hou-Chang Chiu; Joen-Rong Sheu; Kuan-Hung Lin
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

8.  Optimizing nutrient media conditions for continuous production of shoot biomass enriched in major medicinal constituents, amarogentin and mangiferin of endangered medicinal herb, Swertia chirayita.

Authors:  Rolika Gupta; Hemant Sood
Journal:  Vegetos       Date:  2022-08-29

Review 9.  A Review of Swertia chirayita (Gentianaceae) as a Traditional Medicinal Plant.

Authors:  Vijay Kumar; Johannes Van Staden
Journal:  Front Pharmacol       Date:  2016-01-12       Impact factor: 5.810

10.  Amarogentin Inhibits Liver Cancer Cell Angiogenesis after Insufficient Radiofrequency Ablation via Affecting Stemness and the p53-Dependent VEGFA/Dll4/Notch1 Pathway.

Authors:  Yongchuan Zhang; Yinglin Zhang; Jin Wang; Haitao Gu
Journal:  Biomed Res Int       Date:  2020-10-20       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.